Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,088 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,119
- Phase 1824
- Phase 1/Phase 2483
- Phase 3350
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma334
- Acute Myeloid Leukemia291
- Lymphoma183
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Anemia62
- Mantle Cell Lymphoma62
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center59
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama147
- Arizona123
- Florida110
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,088 total
- NCT06933056RecruitingEarly Phase 1
Comparing sotagliflozin to standard blood thinners for heart health
This study compares how well a diabetes drug, sotagliflozin, affects blood clotting compared to common blood thinners like aspirin and clopidogrel. It may help people at risk for heart problems find a safer or more effective treatment.
Ann Arbor, MichiganAges 18–79 - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+ - NCT06985472RecruitingPhase 2
Orelabrutinib and Zuberitamab for newly treated MZL
This trial tests a combination of two targeted drugs, orelabrutinib and zuberitamab, as a first treatment for marginal zone lymphoma (MZL). It aims to see if this combination works well for patients who have not had systemic therapy before.
Guangzhou, GuangdongAges 18 years+ - NCT06944418Recruiting
Eosinophil function in eosinophilic lung disease
This study looks at how a type of white blood cell (eosinophil) works differently in people with eosinophilic lung diseases. It may help doctors understand these conditions better and find new treatments.
Beijing, Beijing MunicipalityAges 18–90 - NCT06982404Recruiting
Heart transplant biopsy study
This study tests whether a small biopsy taken from a donor heart before transplant can predict how well the heart will work after surgery. The goal is to improve transplant success for recipients.
Vienna, State of ViennaAges Any age - NCT06976736Recruiting
Long-term follow-up for TScan TCR-T therapy patients
This study follows participants who previously received a TCR-T cell therapy in a TScan-sponsored trial to monitor long-term effects.
Duarte, CaliforniaAges 18–110 - NCT06952075RecruitingPhase 2
GR1803 for Multiple Myeloma with Soft Tissue Spread
This trial tests an experimental drug called GR1803 for people with multiple myeloma that has spread to soft tissue areas outside the bone. The goal is to see if it can help shrink these tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06926205RecruitingPhase 2
CHOP chemo plus mosunetuzumab for Richter's syndrome first treatment
This trial tests a new immunotherapy drug (mosunetuzumab) combined with standard chemotherapy (CHOP) as the first treatment for Richter's syndrome, a fast-growing lymphoma that can arise from CLL. The goal is to see if this combination helps control the disease better than standard therapy.
Barcelona, BarcelonaAges 18–79 - NCT06832267Recruiting
RMTT chemo for newly diagnosed PCNS lymphoma
This trial tests a combination of four chemotherapy drugs (Rituximab, Methotrexate, Temozolomide, and Thiotepa) as the first treatment for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma. It aims to see if this regimen is safe and effective for patients who have not had any prior systemic therapy.
Hangzhou, ZhejiangAges 18–75 - NCT06831058RecruitingPhase 2
Efgartigimod for preventing iTTP relapses
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Minneapolis, MinnesotaAges 18 years+ - NCT06848569RecruitingPhase 2
Sintilimab plus chemotherapy for pediatric Hodgkin lymphoma
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
Guangzhou, GuangdongAges 1–18 - NCT06820177RecruitingPhase 4
Tranexamic acid to reduce bleeding during abortion or miscarriage
This trial is testing if a medicine called tranexamic acid (TXA) can help reduce bleeding during a second-trimester abortion or miscarriage procedure. The goal is to make the procedure safer for patients.
San Diego, CaliforniaAges 18 years+ - NCT06861257Recruiting
Treosulfan monitoring in pediatric stem cell transplant
This study watches how the chemotherapy drug Treosulfan works in children getting a stem cell transplant. The goal is to make sure the dose is just right for each child.
Bologna, bOLOGNAAges Up to 18 years - NCT06814444Recruiting
Immune system study in acute leukemia
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
Bologna, BolognaAges 18 years+ - NCT06759961Recruiting
Outcomes after kidney transplant for a blood vessel condition
This study looks at outcomes after kidney transplant for a rare blood vessel condition called thrombotic microangiopathy. It aims to learn more about how patients do after transplant at a specific center in Bologna, Italy.
Bologna, BOAges 18 years+ - NCT06769191RecruitingEarly Phase 1
CD7 car-t, stem cell transplant, and kidney transplant for SIOD
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Hangzhou, ZhejiangAges Any age - NCT06748586Recruiting
Hyperbaric oxygen therapy and stem cell study
This study checks if hyperbaric oxygen therapy (HBOT) increases the number of stem cells circulating in your blood. You may qualify if you are already scheduled for HBOT for another reason and are willing to give blood samples.
ZrifinAges 20–80 - NCT06713811Recruiting
Electronic monitoring to help you take your blood meds
This trial is testing if a special electronic device can help you remember to take your oral medications for blood disorders. It's for people who need to take pills for at least 6 months and who have internet access.
AmiensAges 18 years+ - NCT06708130Recruiting
Stem cell transplant tracking study
This study tracks patients who have had or are planning to have a stem cell transplant. It helps doctors learn more about long-term outcomes and improve care for future patients.
Shanghai, Shanghai MunicipalityAges Any age - NCT06737250RecruitingPhase 2
Testing a new drug combo for relapsed brain lymphoma
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
BusanAges 19–80 - NCT06781450Recruiting
Study of immunotherapy for relapsed chest lymphoma
This study looks at how well two immunotherapy medicines—pembrolizumab alone or nivolumab combined with brentuximab vedotin—work for people with a type of lymphoma in the chest that has come back or not responded to treatment. It uses real-world data from patients who received these treatments outside of a clinical trial.
Bologna, BolognaAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06642792RecruitingPhase 1/Phase 2
Study of AK129 with or without AK117 for Hodgkin lymphoma after PD-1 treatment
This trial tests a new drug, AK129, alone or with another drug called AK117, for people with classic Hodgkin lymphoma that has not responded to or stopped responding to PD-1/L1 inhibitor therapy. The goal is to see if these combinations can help control the cancer.
BeijingAges 18 years+ - NCT06610344Recruiting
BHB supplement with CAR-T for lymphoma
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,088 recruiting hematology studies from the U.S. registry right now, out of 7,677 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.